catalyst calendar
PROMIS NEUROSCIENCES INC · Data as of 2026-10-25
4Q26
As a highly esteemed member of the investment community, Slanix's reputation, institutional knowledge and wealth of experience and insights will be invaluable as the Company approaches its key inflection points, with planned data readouts in 2Q26 and 4Q26 from its PRECISE-AD trial evaluating PMN310 in AD and as the Company advances towards late-stage clinical development.Source filing
Q1 2027
Completion of all patient visits is expected in the fourth quarter of 2026, with unblinded 12-month topline data, including the full safety data set, a detailed panel of biomarkers, and cognitive outcomes, anticipated in the first quarter of 2027 following database lock and statistical analysis.Source filing
Nov 16–Nov 19
Participation and presentations at multiple investor and medical conferences, including Clinical Trials on AD (CTAD)Source filing